Armstrong, April W., Mark Lebwohl, Jerry Bagel, Todd Schlesinger, Subhashis Banerjee, Renata M. Kisa, Thomas Scharnitz, Kim Hoyt, and Bruce Strober. 2023. “Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI)”. SKIN The Journal of Cutaneous Medicine 7 (2):s120. https://doi.org/10.25251/skin.7.supp.120.